Trump administration unveils plans to lower U.S. drug prices through TrumpRx.com and 'Most Favored Nation' pricing strategy.
Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
Trump eyes 2026 midterms as key 2024 races drive political climate, with Democrats holding early lead for control of Congress amid concerns over economy and constitutional protections.
Trump administration unveils plans to lower U.S. drug prices through TrumpRx.com and 'Most Favored Nation' pricing strategy.
Novo Nordisk launches a rival $56.50 bid to acquire U.S. obesity biotech Metsera, challenging Pfizer's existing agreement and sparking a bidding war over Metsera's promising GLP-1 pipeline.
Trump eyes 2026 midterms as key 2024 races drive political climate, with Democrats holding early lead for control of Congress amid concerns over economy and constitutional protections.